BrainChild Bio raises $116 million to fund pivotal pediatric brain tumor CAR-T trial
BrainChild Bio, a Seattle-based biotech, announced it has secured $116 million in financing to support a pivotal clinical trial of its CAR-T therapy aimed at pediatric brain tumors.
The funding round is intended to move the company toward a commercial-stage status and to advance the cell therapy, which the company says is designed to behave more like a small-molecule drug for brain tumors.
CEO Steven Brugger and CSO Michael Jensen highlighted that the capital will enable the trial’s enrollment and further development, positioning the firm to address an unmet need in pediatric oncology.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “BrainChild Bio gets $116M for pivotal trial of pediatric brain tumor CAR-T”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that